Read by QxMD icon Read

dentate nucleus gadolinium deposit

Jessica Lohrke, Anna-Lena Frisk, Thomas Frenzel, Laura Schöckel, Martin Rosenbruch, Gregor Jost, Diana Constanze Lenhard, Martin A Sieber, Volker Nischwitz, Astrid Küppers, Hubertus Pietsch
OBJECTIVES: Retrospective studies in patients with primary brain tumors or other central nervous system pathologies as well as postmortem studies have suggested that gadolinium (Gd) deposition occurs in the dentate nucleus (DN) and globus pallidus (GP) after multiple administrations of primarily linear Gd-based contrast agents (GBCAs). However, this deposition has not been associated with any adverse effects or histopathological alterations. The aim of this preclinical study was to systematically examine differences between linear and macrocyclic GBCAs in their potential to induce changes in brain and skin histology including Gd distribution in high spatial resolution...
March 20, 2017: Investigative Radiology
Cyprian Olchowy, Kamil Cebulski, Mateusz Łasecki, Radosław Chaber, Anna Olchowy, Krzysztof Kałwak, Urszula Zaleska-Dorobisz
BACKGROUND AND PURPOSE: Gadolinium based contrast agents (GBCAs) are widely used in magnetic resonance imaging, but recently, high signal intensity in the cerebellum structures was reported after repeated administrations of contrast- enhanced magnetic resonance images. The aim of this systematic review was to investigate the association between increased signal intensity in the dentate nucleus and globus pallidus in the brain and repeated administrations of GBCAs. Additionally, we focused on possible short- and long-term consequences of gadolinium use in those patients...
2017: PloS One
Kyle Bauer, Alaina Lathrum, Osama Raslan, Patrick V Kelly, Yihua Zhou, Debra Hewing, Crystal Botkin, James A Turner, Medhat Osman
Gadolinium is toxic and to avoid its deposition in tissues, it must be chemically bonded with nonmetal ions to facilitate its excretion by the kidneys. High signal intensity in the dentate nucleus (DN) and globus pallidus (GP) on unenhanced T1-weighted MR images has been both morphologically and pathologically linked to gadolinium-based contrast agent (GBCA) retention in the brain. The purpose of this study was to determine whether repeated administrations of GBCA would affect the uptake of (18)F-FDG in the DN and GP on PET/CT...
March 2017: Journal of Nuclear Medicine Technology
Hirofumi Kuno, Hernán Jara, Karen Buch, Muhammad Mustafa Qureshi, Margaret N Chapman, Osamu Sakai
Purpose To assess the association of global and regional brain relaxation times in patients with prior exposure to linear gadolinium-based contrast agents (GBCAs). Materials and Methods The institutional review board approved this cross-sectional study. Thirty-five patients (nine who had received GBCA gadopentetate dimeglumine injections previously [one to eight times] and 26 patients who did not) who underwent brain magnetic resonance (MR) imaging with a mixed fast spin-echo pulse sequence were assessed. The whole brain was segmented according to white and gray matter by using a dual-clustering algorithm...
April 2017: Radiology
Ali Yusuf Öner, Berrak Barutcu, Şükrü Aykol, Emin Turgut Tali
OBJECTIVES: There have been recent studies evaluating brain magnetic resonance imaging changes in patients with normal renal function, after intravenous administration of gadolinium-based contrast agents (GBCAs). Their findings were supported by histological evidence as well and brought a new vision concerning what needs to be learned to provide better patient care. In this report, we aim to present brain magnetic resonance imaging changes after intrathecal administration of a linear ionic agent (gadopentetate dimeglumine)...
October 13, 2016: Investigative Radiology
Zaw Aung Khant, Toshinori Hirai, Yoshihito Kadota, Rie Masuda, Takanori Yano, Minako Azuma, Yukiko Suzuki, Kuniyuki Tashiro
We report a 34-year-old male who manifested T1 shortening of the cerebral cortices after more than 86 contrast-enhanced MRI studies. We observed high-signal intensity (SI) on T1-weighted images (T1WIs) not only in the globus pallidus, dentate nucleus, and pulvinar of thalamus, but also in the cortices of the pre- and post-central gyri and around the calcarine sulcus. High SI in the cerebral cortices was not clearly demonstrated on T1WI scans performed 11 years earlier. The high SI we observed in these areas of the brain corresponded to areas with a normal iron-deposition predilection...
January 10, 2017: Magnetic Resonance in Medical Sciences: MRMS
Joana Ramalho, Miguel Ramalho, Mamdoh AlObaidy, Richard C Semelka
Over the last 2years several studies have been published regarding gadolinium deposition in brain structures in patients with normal renal function after repeated administrations of gadolinium-based contrast agents (GBCAs). Most of the publications are magnetic resonance imaging (MRI) based retrospective studies, where gadolinium deposition may be indirectly measured by evaluating changes in T1 signal intensity (SI) in brain tissue, particularly in the dentate nucleus (DN) and/or globus pallidi (GP). The direct correlation between T1 signal changes and gadolinium deposition was validated by human pathology studies...
September 27, 2016: Magnetic Resonance Imaging
Philipp Eisele, Angelika Alonso, Kristina Szabo, Anne Ebert, Melissa Ong, Stefan O Schoenberg, Achim Gass
Recently, several studies reported increased signal intensity (SI) in the dentate nucleus (DN) after repeated application of gadolinium-based contrast agents (GBCAs), suggesting a deposition of gadolinium in this location. Patients with relapsing-remitting multiple sclerosis (RRMS) frequently show increased permeability of the blood-brain barrier as part of the inflammatory process in the brain parenchyma, which theoretically might increase the risk of gadolinium deposition. In this retrospective study, we investigated a possible increasing SI in the DN after repeated administrations of the macrocyclic contrast agent gadoterate meglumine...
September 2016: Medicine (Baltimore)
Ludwig Schlemm, Claudia Chien, Judith Bellmann-Strobl, Jan Dörr, Jens Wuerfel, Alexander U Brandt, Friedemann Paul, Michael Scheel
BACKGROUND: Previous studies have postulated an association between dentate nucleus T1 hyperintensity and multiple sclerosis (MS)-related progressive neurodegeneration. Therefore, MS patients have been excluded from most studies investigating brain deposition of gadolinium-based contrast agents (GBCAs). OBJECTIVE: To study the hypothesis that dentate nucleus T1 hyperintensity in MS patients is associated with GBCA administration. METHODS: In a cohort of 97 MS patients, the dentate-to-pons signal intensity ratio (DPSIR) was calculated for 265 consecutive T1-weighted magnetic resonance (MR) scans (including sessions with and without the administration of GBCA)...
September 1, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Takuya Hinoda, Yasutaka Fushimi, Tomohisa Okada, Yoshiki Arakawa, Chunlei Liu, Akira Yamamoto, Tsutomu Okada, Kazumichi Yoshida, Susumu Miyamoto, Kaori Togashi
PURPOSE: Gadolinium deposition in dentate nucleus (DN) has been reported after serial administration of gadolinium-based contrast agents (GBCAs). Gadolinium complexes have paramagnetic properties; therefore, we evaluated susceptibility changes of gadolinium deposition in DN using quantitative susceptibility mapping (QSM) for patients after serial administration of GBCAs. MATERIALS AND METHODS: In all, 48 patients with brain tumors, who had had serial GBCA administrations (GBCA group), and 48 healthy volunteers without any history of GBCA administrations (non-GBCA group) were enrolled in this study...
September 24, 2016: Journal of Magnetic Resonance Imaging: JMRI
Alexander Radbruch
In December 2013, a groundbreaking study by Kanda et al. was published showing that the serial injection of gadolinium based contrast agents (GBCAs) is correlated with a signal intensity increase in the dentate nucleus (DN) and the globus pallidus (GP) on unenhanced T1 weighted MR images. Subsequent studies by Kanda et al. and McDonald et al. on brain tissue from deceased patients provided evidence that the reported signal intensity increase in the brain correlates with gadolinium deposits in the brain tissue...
September 11, 2016: Magnetic Resonance Imaging
Tomonori Kanda, Yudai Nakai, Hiroshi Oba, Keiko Toyoda, Kazuhiro Kitajima, Shigeru Furui
Gadolinium is highly toxic. Gadolinium-based contrast agents (GBCAs) consist of gadolinium ions and a chelating agent that binds the gadolinium ion tightly in order not to manifest its toxicity. Knowledge regarding gadolinium deposition in patients with normal renal function has advanced dramatically. Since 2014, increasing attention has been given to residual gadolinium known to accumulate in the tissues of patients with normal renal function. High signal intensity on T1-weighted images (T1WI) in the dentate nucleus, globus pallidus, and pulvinar region of the thalamus correlate roughly with the number of previous GBCA administrations...
September 8, 2016: Magnetic Resonance Imaging
D R Roberts, A R Chatterjee, M Yazdani, B Marebwa, T Brown, H Collins, G Bolles, J M Jenrette, P J Nietert, X Zhu
BACKGROUND AND PURPOSE: While there have been recent reports of brain retention of gadolinium following gadolinium-based contrast agent administration in adults, a retrospective series of pediatric patients has not previously been reported, to our knowledge. We investigated the relationship between the number of prior gadolinium-based contrast agent doses and increasing T1 signal in the dentate nucleus on unenhanced T1-weighted MR imaging. We hypothesized that despite differences in pediatric physiology and the smaller gadolinium-based contrast agent doses that pediatric patients are typically administered based on weighted-adjusted dosing, the pediatric brain would also demonstrate dose-dependent increasing T1 signal in the dentate nucleus...
December 2016: AJNR. American Journal of Neuroradiology
Houchun H Hu, Amber Pokorney, Richard B Towbin, Jeffrey H Miller
BACKGROUND: Recent reports have suggested residual gadolinium deposition in the brain in subjects undergoing multiple contrast-enhanced MRI exams. These findings have raised some concerns regarding gadolinium-based contrast agent (GBCA) usage and retention in brain tissues. OBJECTIVE: To summarize findings of hyperintense brain structures on precontrast T1-weighted images in 21 children undergoing multiple GBCA MRI exams. MATERIALS AND METHODS: This retrospective study involved 21 patients, each of whom received multiple MRI examinations (range: 5-37 exams) with GBCA over the course of their medical treatment (duration from first to most recent exam: 1...
October 2016: Pediatric Radiology
Marie-Luise Kromrey, Kim Rouven Liedtke, Till Ittermann, Sönke Langner, Michael Kirsch, Werner Weitschies, Jens-Peter Kühn
PURPOSE: To investigate if application of macrocyclic gadolinium-based contrast agents in volunteers is associated with neuronal deposition detected by magnetic resonance imaging in a 5-year longitudinal survey. MATERIALS AND METHODS: Three hundred eighty-seven volunteers who participated in a population-based study were enrolled. Subjects underwent plain T1-weighted brain MRI at baseline and 5 years later with identical sequence parameters. At baseline, 271 participants additionally received intravenous injection of the macrocyclic contrast agent gadobutrol (1...
February 2017: European Radiology
J Ramalho, M Ramalho, M AlObaidy, R H Nunes, M Castillo, R C Semelka
BACKGROUND AND PURPOSE: Different T1-weighted sequences have been used for qualitative and quantitative evaluation of T1 signal intensity related to gadolinium deposition in the dentate nucleus in patients who underwent several enhanced MR imaging studies. Our purpose was to perform an intraindividual qualitative and quantitative comparison between T1-weighted spin-echo and 3D magnetization-prepared rapid acquisition of gradient echo sequences in patients who had multiple exposures to gadodiamide...
August 2016: AJNR. American Journal of Neuroradiology
Tomonori Kanda, Yudai Nakai, Shuri Aoki, Hiroshi Oba, Keiko Toyoda, Kazuhiro Kitajima, Shigeru Furui
Various metals are essential nutrients in humans, and metal shortages lead to a variety of deficiency diseases. Metal concentration abnormalities may cause metal deposition in the brain, and magnetic resonance imaging (MRI) is the most potent and sensitive technique now available for detecting metal deposition given the difficulties associated with performing brain tissue biopsy. However, the brain contains many kinds of metals that affect the signal intensity of MRI, which has led to numerous misunderstandings in the history of metal analysis...
April 2016: Japanese Journal of Radiology
Joana Ramalho, Richard C Semelka, Mamdoh AlObaidy, Miguel Ramalho, Renato H Nunes, Mauricio Castillo
OBJECTIVES: To evaluate the impact of previous administration of gadodiamide and neural tissue gadolinium deposition in patients who received gadobenate dimeglumine. METHODS: Our population included 62 patients who underwent at least three administrations of gadobenate dimeglumine, plus an additional contrast-enhanced last MRI for reference, divided into two groups: group 1, patients who in addition to gadobenate dimeglumine administrations had prior exposure to multiple doses of gadodiamide; group 2, patients without previous exposure to other gadolinium-based contrast agent (GBCAs)...
November 2016: European Radiology
Dragan Stojanov, Aleksandra Aracki-Trenkic, Daniela Benedeto-Stojanov
INTRODUCTION: Gadolinium-based contrast agents (GBCAs) have been used clinically since 1988 for contrast-enhanced magnetic resonance imaging (CE-MRI). Generally, GBCAs are considered to have an excellent safety profile. However, GBCA administration has been associated with increased occurrence of nephrogenic systemic fibrosis (NSF) in patients with severely compromised renal function, and several studies have shown evidence of gadolinium deposition in specific brain structures, the globus pallidus and dentate nucleus, in patients with normal renal function...
May 2016: Neuroradiology
Tomonori Kanda, Hiroshi Oba, Keiko Toyoda, Kazuhiro Kitajima, Shigeru Furui
Gadolinium-based contrast agents (GBCAs) consist of gadolinium ions and a chelating agent that binds the gadolinium ion tightly so that its toxicity is not manifested. However, in 2013, an association between brain MRI abnormalities and a history of GBCA administration was first reported. Even in patients with normal renal function, increased signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images showed a positive correlation with previous exposure to linear chelate type GBCAs, but not to macrocyclic chelate type ones...
January 2016: Japanese Journal of Radiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"